IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE

VELOXIS PHARMACEUTICALS, INC.,)	
Plaintiff,)	
v.)	C.A. No. 22-909 (JDW)
ACCORD HEALTHCARE, INC. and INTAS PHARMACEUTICALS LTD.,)	
Defendants.)	

CONSENT JUDGMENT

Plaintiff Veloxis Pharmaceuticals, Inc. ("Plaintiff") and Defendants Accord Healthcare, Inc. and Intas Pharmaceuticals Ltd. (collectively, "Defendants"), the parties in the above-captioned action, hereby stipulate and consent to entry of judgment and an injunction in this action as follows:

IT IS this 24th day of January , 2024:

ORDERED, ADJUDGED, AND DECREED as follows:

- 1. This Court has jurisdiction over the subject matter of the above action and has personal jurisdiction over the parties for purposes of this action only, including as set forth below in Paragraph 6 of this Consent Judgement.
- 2. As used in this Consent Judgment, the term "Accord ANDA Product" shall mean the tacrolimus drug products manufactured, sold, offered for sale, marketed, or distributed pursuant to Abbreviated New Drug Application No. 217255.
- 3. As used in this Consent Judgment, the term "Patents-in-Suit" shall mean U.S. Patent Nos. 8,685,998; 9,549,918; 10,166,190; 10,864,199; 11,110,081; 11,123,331; and 11,419,823.

- 4. Until expiration of the Patents-in-Suit, Defendants, including any of their successors and assigns, are enjoined from infringing the Patents-in-Suit, on their own part or through any third party on their behalf, by making, having made, using, selling, offering to sell, importing, or distributing of the Accord ANDA Product, unless and to the extent otherwise specifically authorized by Veloxis, and are further enjoined from assisting or cooperating with any third parties in connection with any infringement of the Patents-in-Suit by any such third parties, unless and to the extent otherwise specifically authorized by Veloxis.
- 5. Compliance with this Consent Judgment may be enforced by Veloxis and its respective successors in interest or assigns.
- 6. All claims, counterclaims, affirmative defenses and demands in this action are hereby dismissed with prejudice and without costs, disbursements or attorneys' fees to any party.
- 7. Nothing herein prohibits or is intended to prohibit Defendants from maintaining a "Paragraph IV Certification" pursuant to 21 U.S.C. § 355(j)(2)(A)(vii)(IV) or pursuant to 21 C.F.R. § 314.94(a)(12) with respect to the Patents-in-Suit.
- 8. Nothing herein restricts or is intended to restrict the U.S. Food and Drug Administration from approving the Accord ANDA No. 217255 at any time.

We hereby consent to the form and entry of this Judgment:

MORRIS, NICHOLS, ARSHT & TUNNELL LLP RICHARDS, LAYYTON & FINGER, P.A.

/s/Jeremy A. Tigan

/s/ Sara M. Metzler

Jack B. Blumenfeld (#1014) Jeremy A. Tigan (#5239) 1201 North Market Street P.O. Box 1347 Wilmington, DE 19899 (302) 658-9200 jblumenfeld@morrisnichols.com jtigan@morrisnichols.com

Kelly E. Farnan (#4395) Sara M. Metzler (#6509) One Rodney Square 920 North King Street Wilmington, DE 19801 (302) 651-7700 farnan@rlf.com metzler@rlf.com

Attorneys for Plaintiff Veloxis Pharmaceuticals, Attorneys for Defendants Accord Healthcare, Inc.

Inc. and Intas Pharmaceuticals Ltd.

January 22, 2024

SO ORDERED:

/s/ Joshua D. Wolson

Joshua D. Wolson, U.S.D.J.